Loading…
Maximum a posteriori Bayesian estimation of oral cyclosporin pharmacokinetics in patients with stable renal transplants
To develop a maximum a posteriori probability (MAP) Bayesian estimator for the pharmacokinetics of oral cyclosporin, based on only three timepoints, and evaluate its performance with respect to a full-profile nonlinear regression approach. 20 adult patients with stable renal transplants given orally...
Saved in:
Published in: | Clinical pharmacokinetics 2002, Vol.41 (1), p.71-80 |
---|---|
Main Authors: | , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c341t-b9423419aa3e8a6b32ee2287014b7c482c7a23f4250eb5695a5bceed94137e6e3 |
---|---|
cites | cdi_FETCH-LOGICAL-c341t-b9423419aa3e8a6b32ee2287014b7c482c7a23f4250eb5695a5bceed94137e6e3 |
container_end_page | 80 |
container_issue | 1 |
container_start_page | 71 |
container_title | Clinical pharmacokinetics |
container_volume | 41 |
creator | LEGER, Frédéric DEBORD, Jean LE MEUR, Yann ROUSSEAU, Annick BÜCHLER, Mathias LACHATRE, Gérard PAINTAUD, Gilles MARQUET, Pierre |
description | To develop a maximum a posteriori probability (MAP) Bayesian estimator for the pharmacokinetics of oral cyclosporin, based on only three timepoints, and evaluate its performance with respect to a full-profile nonlinear regression approach.
20 adult patients with stable renal transplants given orally administered microemulsified cyclosporin and mycophenolate.
Cyclosporin was assayed by liquid chromatography-mass spectrometry. Nonlinear regression and MAP Bayesian estimation were performed using a home-made program and a previously designed pharmacokinetic model including an S-shaped absorption profile described by a gamma distribution.
MAP Bayesian estimation using the best limited sampling strategy (before administration, and 1 and 3 hours after administration) was compared with nonlinear regression (taken as the reference method) for the prediction of the different pharmacokinetic parameters and exposure indices. Median relative prediction error was -0.49 and -3.42% for area under the concentration-time curve over the administration interval of 12 hours (AUC12) and estimated peak drug concentration (Cmax), respectively (nonsignificant). Relative precision was 2.00 and 4.32%, and correlation coefficient (r) was 0.985 and 0.955, for AUC12 and Cmax, respectively.
This paper reports preliminary results in a stable renal transplant patient population, showing that MAP Bayesian estimation can allow accurate prediction of AUC12 and Cmax with only three samples (0, 1 and 3 hours). Although these results require confirmation by further studies in other clinical settings, using other drug combinations, other analytical methods and commercially available pharmacokinetic software, the method seems promising as a tool for the therapeutic drug monitoring of cyclosporin in clinical practice or for exposure-controlled studies. |
doi_str_mv | 10.2165/00003088-200241010-00006 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71433087</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>71433087</sourcerecordid><originalsourceid>FETCH-LOGICAL-c341t-b9423419aa3e8a6b32ee2287014b7c482c7a23f4250eb5695a5bceed94137e6e3</originalsourceid><addsrcrecordid>eNpFkc1O3DAUha2Kqgy0r1B5U3YB_yVxlgXRFgnUTbuObsyNcJvEqa9HMG_fO2UK3tg6_o7tcyyE1Orc6Ka-UDys8r4yShmnlVbVXmreiI3WbVfpzjRHYqOsNlXdNfZYnBD9YsKz4Z041tqbWnV-Ix7v4CnO21mCXBMVzDHlKC9hhxRhkUglzlBiWmQaZcowybALU6KVsUWuD5BnCOl3XLDEQHKvMY5LIfkYy4OkAsOEMuPC1pJhoXUC3n0v3o4wEX44zKfi55frH1ffqtvvX2-uPt9WwTpdqqFzhhcdgEUPzWANojG-VdoNbXDehBaMHR2nwaFuuhrqISDed07bFhu0p-Ls-dw1pz9bjtPPkQJO_AhMW-pb7Sw32TLon8GQE1HGsV8zR8-7Xqt-X3r_v_T-pfR_UsPWj4c7tsOM96_GQ8sMfDoAQAGmkWsIkV456_iPamv_ArU9jDk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>71433087</pqid></control><display><type>article</type><title>Maximum a posteriori Bayesian estimation of oral cyclosporin pharmacokinetics in patients with stable renal transplants</title><source>Springer Nature</source><creator>LEGER, Frédéric ; DEBORD, Jean ; LE MEUR, Yann ; ROUSSEAU, Annick ; BÜCHLER, Mathias ; LACHATRE, Gérard ; PAINTAUD, Gilles ; MARQUET, Pierre</creator><creatorcontrib>LEGER, Frédéric ; DEBORD, Jean ; LE MEUR, Yann ; ROUSSEAU, Annick ; BÜCHLER, Mathias ; LACHATRE, Gérard ; PAINTAUD, Gilles ; MARQUET, Pierre</creatorcontrib><description>To develop a maximum a posteriori probability (MAP) Bayesian estimator for the pharmacokinetics of oral cyclosporin, based on only three timepoints, and evaluate its performance with respect to a full-profile nonlinear regression approach.
20 adult patients with stable renal transplants given orally administered microemulsified cyclosporin and mycophenolate.
Cyclosporin was assayed by liquid chromatography-mass spectrometry. Nonlinear regression and MAP Bayesian estimation were performed using a home-made program and a previously designed pharmacokinetic model including an S-shaped absorption profile described by a gamma distribution.
MAP Bayesian estimation using the best limited sampling strategy (before administration, and 1 and 3 hours after administration) was compared with nonlinear regression (taken as the reference method) for the prediction of the different pharmacokinetic parameters and exposure indices. Median relative prediction error was -0.49 and -3.42% for area under the concentration-time curve over the administration interval of 12 hours (AUC12) and estimated peak drug concentration (Cmax), respectively (nonsignificant). Relative precision was 2.00 and 4.32%, and correlation coefficient (r) was 0.985 and 0.955, for AUC12 and Cmax, respectively.
This paper reports preliminary results in a stable renal transplant patient population, showing that MAP Bayesian estimation can allow accurate prediction of AUC12 and Cmax with only three samples (0, 1 and 3 hours). Although these results require confirmation by further studies in other clinical settings, using other drug combinations, other analytical methods and commercially available pharmacokinetic software, the method seems promising as a tool for the therapeutic drug monitoring of cyclosporin in clinical practice or for exposure-controlled studies.</description><identifier>ISSN: 0312-5963</identifier><identifier>EISSN: 1179-1926</identifier><identifier>DOI: 10.2165/00003088-200241010-00006</identifier><identifier>PMID: 11825098</identifier><identifier>CODEN: CPKNDH</identifier><language>eng</language><publisher>Auckland: Adis international</publisher><subject>Administration, Oral ; Adult ; Aged ; Area Under Curve ; Bayes Theorem ; Biological and medical sciences ; Biological Availability ; Cyclosporine - administration & dosage ; Cyclosporine - blood ; Cyclosporine - pharmacokinetics ; Emulsions ; Female ; Gas Chromatography-Mass Spectrometry ; Humans ; Immunomodulators ; Immunosuppressive Agents - administration & dosage ; Immunosuppressive Agents - blood ; Immunosuppressive Agents - pharmacokinetics ; Kidney Transplantation ; Likelihood Functions ; Male ; Medical sciences ; Middle Aged ; Models, Statistical ; Nonlinear Dynamics ; Pharmacology. Drug treatments</subject><ispartof>Clinical pharmacokinetics, 2002, Vol.41 (1), p.71-80</ispartof><rights>2002 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c341t-b9423419aa3e8a6b32ee2287014b7c482c7a23f4250eb5695a5bceed94137e6e3</citedby><cites>FETCH-LOGICAL-c341t-b9423419aa3e8a6b32ee2287014b7c482c7a23f4250eb5695a5bceed94137e6e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,4021,27921,27922,27923</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=13496353$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11825098$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>LEGER, Frédéric</creatorcontrib><creatorcontrib>DEBORD, Jean</creatorcontrib><creatorcontrib>LE MEUR, Yann</creatorcontrib><creatorcontrib>ROUSSEAU, Annick</creatorcontrib><creatorcontrib>BÜCHLER, Mathias</creatorcontrib><creatorcontrib>LACHATRE, Gérard</creatorcontrib><creatorcontrib>PAINTAUD, Gilles</creatorcontrib><creatorcontrib>MARQUET, Pierre</creatorcontrib><title>Maximum a posteriori Bayesian estimation of oral cyclosporin pharmacokinetics in patients with stable renal transplants</title><title>Clinical pharmacokinetics</title><addtitle>Clin Pharmacokinet</addtitle><description>To develop a maximum a posteriori probability (MAP) Bayesian estimator for the pharmacokinetics of oral cyclosporin, based on only three timepoints, and evaluate its performance with respect to a full-profile nonlinear regression approach.
20 adult patients with stable renal transplants given orally administered microemulsified cyclosporin and mycophenolate.
Cyclosporin was assayed by liquid chromatography-mass spectrometry. Nonlinear regression and MAP Bayesian estimation were performed using a home-made program and a previously designed pharmacokinetic model including an S-shaped absorption profile described by a gamma distribution.
MAP Bayesian estimation using the best limited sampling strategy (before administration, and 1 and 3 hours after administration) was compared with nonlinear regression (taken as the reference method) for the prediction of the different pharmacokinetic parameters and exposure indices. Median relative prediction error was -0.49 and -3.42% for area under the concentration-time curve over the administration interval of 12 hours (AUC12) and estimated peak drug concentration (Cmax), respectively (nonsignificant). Relative precision was 2.00 and 4.32%, and correlation coefficient (r) was 0.985 and 0.955, for AUC12 and Cmax, respectively.
This paper reports preliminary results in a stable renal transplant patient population, showing that MAP Bayesian estimation can allow accurate prediction of AUC12 and Cmax with only three samples (0, 1 and 3 hours). Although these results require confirmation by further studies in other clinical settings, using other drug combinations, other analytical methods and commercially available pharmacokinetic software, the method seems promising as a tool for the therapeutic drug monitoring of cyclosporin in clinical practice or for exposure-controlled studies.</description><subject>Administration, Oral</subject><subject>Adult</subject><subject>Aged</subject><subject>Area Under Curve</subject><subject>Bayes Theorem</subject><subject>Biological and medical sciences</subject><subject>Biological Availability</subject><subject>Cyclosporine - administration & dosage</subject><subject>Cyclosporine - blood</subject><subject>Cyclosporine - pharmacokinetics</subject><subject>Emulsions</subject><subject>Female</subject><subject>Gas Chromatography-Mass Spectrometry</subject><subject>Humans</subject><subject>Immunomodulators</subject><subject>Immunosuppressive Agents - administration & dosage</subject><subject>Immunosuppressive Agents - blood</subject><subject>Immunosuppressive Agents - pharmacokinetics</subject><subject>Kidney Transplantation</subject><subject>Likelihood Functions</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Models, Statistical</subject><subject>Nonlinear Dynamics</subject><subject>Pharmacology. Drug treatments</subject><issn>0312-5963</issn><issn>1179-1926</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><recordid>eNpFkc1O3DAUha2Kqgy0r1B5U3YB_yVxlgXRFgnUTbuObsyNcJvEqa9HMG_fO2UK3tg6_o7tcyyE1Orc6Ka-UDys8r4yShmnlVbVXmreiI3WbVfpzjRHYqOsNlXdNfZYnBD9YsKz4Z041tqbWnV-Ix7v4CnO21mCXBMVzDHlKC9hhxRhkUglzlBiWmQaZcowybALU6KVsUWuD5BnCOl3XLDEQHKvMY5LIfkYy4OkAsOEMuPC1pJhoXUC3n0v3o4wEX44zKfi55frH1ffqtvvX2-uPt9WwTpdqqFzhhcdgEUPzWANojG-VdoNbXDehBaMHR2nwaFuuhrqISDed07bFhu0p-Ls-dw1pz9bjtPPkQJO_AhMW-pb7Sw32TLon8GQE1HGsV8zR8-7Xqt-X3r_v_T-pfR_UsPWj4c7tsOM96_GQ8sMfDoAQAGmkWsIkV456_iPamv_ArU9jDk</recordid><startdate>2002</startdate><enddate>2002</enddate><creator>LEGER, Frédéric</creator><creator>DEBORD, Jean</creator><creator>LE MEUR, Yann</creator><creator>ROUSSEAU, Annick</creator><creator>BÜCHLER, Mathias</creator><creator>LACHATRE, Gérard</creator><creator>PAINTAUD, Gilles</creator><creator>MARQUET, Pierre</creator><general>Adis international</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>2002</creationdate><title>Maximum a posteriori Bayesian estimation of oral cyclosporin pharmacokinetics in patients with stable renal transplants</title><author>LEGER, Frédéric ; DEBORD, Jean ; LE MEUR, Yann ; ROUSSEAU, Annick ; BÜCHLER, Mathias ; LACHATRE, Gérard ; PAINTAUD, Gilles ; MARQUET, Pierre</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c341t-b9423419aa3e8a6b32ee2287014b7c482c7a23f4250eb5695a5bceed94137e6e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Administration, Oral</topic><topic>Adult</topic><topic>Aged</topic><topic>Area Under Curve</topic><topic>Bayes Theorem</topic><topic>Biological and medical sciences</topic><topic>Biological Availability</topic><topic>Cyclosporine - administration & dosage</topic><topic>Cyclosporine - blood</topic><topic>Cyclosporine - pharmacokinetics</topic><topic>Emulsions</topic><topic>Female</topic><topic>Gas Chromatography-Mass Spectrometry</topic><topic>Humans</topic><topic>Immunomodulators</topic><topic>Immunosuppressive Agents - administration & dosage</topic><topic>Immunosuppressive Agents - blood</topic><topic>Immunosuppressive Agents - pharmacokinetics</topic><topic>Kidney Transplantation</topic><topic>Likelihood Functions</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Models, Statistical</topic><topic>Nonlinear Dynamics</topic><topic>Pharmacology. Drug treatments</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>LEGER, Frédéric</creatorcontrib><creatorcontrib>DEBORD, Jean</creatorcontrib><creatorcontrib>LE MEUR, Yann</creatorcontrib><creatorcontrib>ROUSSEAU, Annick</creatorcontrib><creatorcontrib>BÜCHLER, Mathias</creatorcontrib><creatorcontrib>LACHATRE, Gérard</creatorcontrib><creatorcontrib>PAINTAUD, Gilles</creatorcontrib><creatorcontrib>MARQUET, Pierre</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical pharmacokinetics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>LEGER, Frédéric</au><au>DEBORD, Jean</au><au>LE MEUR, Yann</au><au>ROUSSEAU, Annick</au><au>BÜCHLER, Mathias</au><au>LACHATRE, Gérard</au><au>PAINTAUD, Gilles</au><au>MARQUET, Pierre</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Maximum a posteriori Bayesian estimation of oral cyclosporin pharmacokinetics in patients with stable renal transplants</atitle><jtitle>Clinical pharmacokinetics</jtitle><addtitle>Clin Pharmacokinet</addtitle><date>2002</date><risdate>2002</risdate><volume>41</volume><issue>1</issue><spage>71</spage><epage>80</epage><pages>71-80</pages><issn>0312-5963</issn><eissn>1179-1926</eissn><coden>CPKNDH</coden><abstract>To develop a maximum a posteriori probability (MAP) Bayesian estimator for the pharmacokinetics of oral cyclosporin, based on only three timepoints, and evaluate its performance with respect to a full-profile nonlinear regression approach.
20 adult patients with stable renal transplants given orally administered microemulsified cyclosporin and mycophenolate.
Cyclosporin was assayed by liquid chromatography-mass spectrometry. Nonlinear regression and MAP Bayesian estimation were performed using a home-made program and a previously designed pharmacokinetic model including an S-shaped absorption profile described by a gamma distribution.
MAP Bayesian estimation using the best limited sampling strategy (before administration, and 1 and 3 hours after administration) was compared with nonlinear regression (taken as the reference method) for the prediction of the different pharmacokinetic parameters and exposure indices. Median relative prediction error was -0.49 and -3.42% for area under the concentration-time curve over the administration interval of 12 hours (AUC12) and estimated peak drug concentration (Cmax), respectively (nonsignificant). Relative precision was 2.00 and 4.32%, and correlation coefficient (r) was 0.985 and 0.955, for AUC12 and Cmax, respectively.
This paper reports preliminary results in a stable renal transplant patient population, showing that MAP Bayesian estimation can allow accurate prediction of AUC12 and Cmax with only three samples (0, 1 and 3 hours). Although these results require confirmation by further studies in other clinical settings, using other drug combinations, other analytical methods and commercially available pharmacokinetic software, the method seems promising as a tool for the therapeutic drug monitoring of cyclosporin in clinical practice or for exposure-controlled studies.</abstract><cop>Auckland</cop><pub>Adis international</pub><pmid>11825098</pmid><doi>10.2165/00003088-200241010-00006</doi><tpages>10</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0312-5963 |
ispartof | Clinical pharmacokinetics, 2002, Vol.41 (1), p.71-80 |
issn | 0312-5963 1179-1926 |
language | eng |
recordid | cdi_proquest_miscellaneous_71433087 |
source | Springer Nature |
subjects | Administration, Oral Adult Aged Area Under Curve Bayes Theorem Biological and medical sciences Biological Availability Cyclosporine - administration & dosage Cyclosporine - blood Cyclosporine - pharmacokinetics Emulsions Female Gas Chromatography-Mass Spectrometry Humans Immunomodulators Immunosuppressive Agents - administration & dosage Immunosuppressive Agents - blood Immunosuppressive Agents - pharmacokinetics Kidney Transplantation Likelihood Functions Male Medical sciences Middle Aged Models, Statistical Nonlinear Dynamics Pharmacology. Drug treatments |
title | Maximum a posteriori Bayesian estimation of oral cyclosporin pharmacokinetics in patients with stable renal transplants |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T12%3A19%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Maximum%20a%20posteriori%20Bayesian%20estimation%20of%20oral%20cyclosporin%20pharmacokinetics%20in%20patients%20with%20stable%20renal%20transplants&rft.jtitle=Clinical%20pharmacokinetics&rft.au=LEGER,%20Fr%C3%A9d%C3%A9ric&rft.date=2002&rft.volume=41&rft.issue=1&rft.spage=71&rft.epage=80&rft.pages=71-80&rft.issn=0312-5963&rft.eissn=1179-1926&rft.coden=CPKNDH&rft_id=info:doi/10.2165/00003088-200241010-00006&rft_dat=%3Cproquest_cross%3E71433087%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c341t-b9423419aa3e8a6b32ee2287014b7c482c7a23f4250eb5695a5bceed94137e6e3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=71433087&rft_id=info:pmid/11825098&rfr_iscdi=true |